Integrated care NuVue combines diagnostic imaging with targeted therapeutic delivery for soft-tissue cancers, offering a potential for multi-product contracts with hospitals seeking single-vendor solutions for liver, pancreatic, and other hard-to-treat cancers.

Precision therapy Therapeutic offerings promise high-dose targeting with substantially lower systemic toxicity, presenting a compelling value proposition for oncology centers focused on tumor-specific treatments and improved patient quality of life.

Early-stage traction Current revenue is under one million, indicating a market entry phase with low penetration. This presents a runway for pilot programs, clinical collaborations, and proof-of-concept deployments at cancer centers.

Diagnostic advantage Real-time biopsy needle visualization and precise site-marking capabilities create upsell opportunities with interventional radiology and pathology departments seeking enhanced imaging, accuracy, and workflow efficiency.

Strategic partnerships Smaller team size and a niche focus align with partnering opportunities for major medical device distribu tors, contract manufacturers, and research partnerships that can scale clinical adoption and co-development.